what should be achieved in order to reduce the high data on incident hemodialysis patients indicate the associated mortality in the dialysis population secondary to cardiac risk of death was not different for patients with Hct 33 to Ͻ36% versus Hct 36 to Ͻ39%. Hospitalization risks and associdisease [11] [12] [13] . One study in the literature by Besarab ated costs were significantly less in the patients with Hct 36 to et al has receive considerable attention because it tested Ͻ39%, suggesting that higher Hct values may be less of a the hypothesis that correcting hemodialysis patients' heconcern than previously considered. The current data suggest matocrits from 30% to 42% would reduce mortality and that patents with advanced cardiac disease should avoid Hct values in the normal range. In others, Hcts at least up to 39% morbidity in patients with cardiac disease. The study was appear to be safe and effective. Based on this review, a reasonstopped early because the treatment group mortality was able target Hct range may be 33 to 39%, which balances the not significantly higher than the control group, and that risks and potential benefits.
there was little chance that the primary hypothesis of an improved outcome would be achieved with the time remaining in the trial. This study suggested that there Since recombinant erythropoietin was introduced into may be limits to the level of correction of anemia that clinical practice in 1989 for the treatment of ESRDshould safely be achieved in the dialysis population. related anemia, considerable attention has been spent Given the countering views that a normal hematocrit on determining the appropriate degree of correction of (Hct) should be achieved and also the risks of complete the hemoglobin and the associated clinical benefits. A correction of anemia, this article will review the trial data number of clinical trials have defined the physiologic and observational studies to determine what evidence is changes that occur when the hematocrit level is increased available to address the safety of Hcts between 33% and from the pre-Epoetin era level of less than 30% to hema-36%, and the 42% of a normal population level. tocrits of greater than 30%, and more recently, to hematocrits in the higher ranges of 38-42% [1-5]. The clinical benefits of correcting hematocrits to Ͼ30% have shown THE NORMAL HCT TRIAL IN PATIENTS WITH improved exercise capacity, cognitive function, better CARDIAC DISEASE quality of life, improved cardiac function, and improved
The evidence developed from earlier trials and the sexual function [6] [7] [8] [9] [10] . The physiologic improvements observational studies suggested that patients with cardiac disease, particularly those with left ventricular hypertro-
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et al in 1998 reported on a trial to test the hypothesis questioned as well, but no additional studies have been reported to settle the debate [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . that mortality and morbidity would be reduced in patients with New York Heart Association classification heart disease stage I-III when the Hct was increased to HIGHER HEMATOCRIT LEVELS IN LOW RISK 42% compared with a control group with the Hct sus-POPULATIONS: IMPACT ON QUALITY OF LIFE tained at 30% [14] . Six hundred fifteen and six hundred AND FUNCTIONAL STATUS eighteen prevalent hemodialysis patients were random-Concerns over the lack of benefit of an increased Hct ized to the treatment arms of 30% and 42%, respectively.
in patients with cardiac disease led a number of investiga-The higher Hct group required significantly more Epoetors to reevaluate the clinical limits that can be achieved tin and intravenous iron to achieve the higher Hct levels.
in patients with established heart disease. Moreno et al The primary outcome was time to death or first nonstudied patients without cardiac disease, accessing the fatal myocardial infarction. Secondary outcomes tracked impact of increasing Hct levels over a six-month period hospitalizations with detailed categorizations of the prinas reported in 2000 [25] . This multi-center prospective cipal cause of the admissions. The follow-up period was 6 month interventional trial was performed in patients 29 months, with the study terminated early secondary with a mean Hct of 31%, increasing their Hct to 38.5% to a non-significant higher risk of death (RR ϭ 1.30; CI, assessing their Sickness Impact Profile (SIP) and Karnof-0.09-1.90) in the Hct group 42%. This action will be sky score before and after intervention. One hundred taken since the remaining time in the study would not fifteen patients without significant cardiac disease were offset the trends such that the principal hypothesis could treated with their initial SIP of 8.9 and, after achieving not be proven. Therefore, to reduce the potential risk the higher Hct, the score decreased to 7.25 (P Ͻ 0.001), to the study subjects, the trial was stopped. Less than an 18.5% improvement. Their functional status also im-150 patients (12.1%) had been followed for 24 months proved from a Karnofsky score initially of 75.6 to 78.4 when the trial was stopped. Post hoc analysis showed (P Ͻ 0.01), a 3.7% improvement. Additional information that when the treated patients were divided by Hct level, was presented on their pattern of morbidity from hospithe normal Hct treatment group had higher death rates talizations comparing the previous six months' pattern even though their achieved Hcts were comparable to the with that noted during the six-month intervention. Total low Hct group. The higher death rate finding continued hospitalizations were reduced 58% (P Ͻ 0.05), and total up to Hct levels of 36-39%; however, those patients that hospital days decreased 69% (P Ͻ 0.05). No patient achieved an Hct of 39-41% had a lower death rate. This deaths were noted, and only 11 patients dropped out of later observation may represent select and survivor bias the study secondary to vascular access thrombosis (N ϭ and should be viewed with caution. 9, 5.7%) and hypertension (N ϭ 2, 2%). This study, in The unexplained findings of a higher death rate in the contrast with the Besarab et al study, showed a significant normal Hct treatment arm raised concerns that the trial improvement in both morbidity and patient well-being. may have had an unrecognized confounding element that One possible explanation for these findings may center was not considered. The higher Hct treatment group on the cohort studied. These low risk patients had less resulted in significantly more the intravenous iron being established disease that may have lowered the potential given compared with the control group. The authors risk as the higher Hct levels are achieved. The level of suggested that this confounding effect may contribute anemia correction was also different in the Moreno et the reasons for the differences in the outcomes. Unfortunately, the post hoc nature of the analysis could not be al study, with patients achieving an average of 38.5% compared with the Besarab et al study which targeted used to dismiss the trial findings that the normal Hct group did not benefit with reduced mortality or a morbid-a 42% Hct. Another important comparison between the two studies relates to the early deaths. In the Besarab ity secondary to hospitalizations. The one area of clear finding was related to an increase in vascular access et al normal Hct trial in patients with cardiac disease, approximately 11% of the patients had died or had an thrombosis in the normal Hct group. These findings were not subjected to the same Hct level analysis as was done acute myocardial infarct within the first six months of the study. In contrast, the Moreno et al trial in patients in the mortality report, thereby leaving the issue unresolved. Thus, this trial suggested that patients with car-without cardiac disease had no deaths during the sixmonth treatment phase. The markedly different hospital-diac disease of NYHA class I-III do not benefit from a Hct of 42% compared with an Hct of 30%. Unfortu-ization patterns between the studies at least suggest that Hcts of 38.5% in non-cardiac disease patients are not nately, little else can be gleaned from this study as there appears to be a concern about the use of large doses of only safe but also effective at reducing morbidity. This was the first study to demonstrate improved outcomes IV iron, a suggested risk factor in the general population for cardiac disease. This iron hypothesis has also been in patients with an Hct above the DOQI target of 36%.
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OBSERVATIONAL STUDIES DEMONSTRATING ables included age, gender, co-morbidity, dialysis modality, and prior ESRD time. The outcome was the odds AN ASSOCIATION BETWEEN HCT LEVELS ratio of death in the next year of followup assessed in a AND CLINICAL OUTCOMES logistic regression model. Also, the hospitalization rates In contrast to the above randomized prospective conand total hospital days were evaluated between the three trolled multi-center trial and the prospective interven-Hct ranges. Crude mortality was highest at 16% in the tional study, at least five observational studies have been Hct group of Ͻ27% and was lower at 11% in the Hct published showing a lower associated morbidity and group of Ͼ32%. Cardiovascular death and cerebrovascumortality when the Hct level was greater than 30% [8, lar death were also lowest in the group of Ͼ32%. Hospi-9, 26-28]. The first study demonstrating this association talization days were the lowest on the Hct group of was published in 1997 by Madore et al. This observa-Ͼ32% at 11 days compared with 13 days for the group tional study investigated 18,792 patients who were alive of 27-32% and 16.5 days per patient's year at risk. This at the end of 1992, with three months of biochemical study established the lower associated hospitalization and Hct data available from October, November, and risk when the patients Hct was Ͼ32% compared with December 1992, with followup through 1993. Because lower levels of anemia correction. The findings of lower observational studies must address potential selection cerebral vascular deaths also allayed concerns about the bias, the investigator added increasing amounts of clinipotential risk of hypertension and cerebral vascular cal data to the logistic regression model odds ratio of events when patients' Hcts were corrected to levels death. Three models were run with age, gender, and race above 30% [27] . only, the previous model with albumin and the final Two large national studies from the United States model which added monthly biochemical data and urea were subsequently published by Ma et al and Xia et al reduction ratio. Each of the models gave very similar in 1999 which were companion studies on the same coresults, with the highest odds of death occurring in the hort of Medicare hemodialysis patients from 1993. These patients with hemoglobins of Յ80 g/L (OD: 1.5-2.0) comauthors first reported mortality associations with the secpared with those with hemoglobins of 100-110 g/L. The ond paper addressing the risk of hospitalization. These risk decreased to 25% higher at hemoglobins of 90-100 investigators evaluated prevalent Medicare hemodialysis g/L and were not significantly different for those hemopatients that survived the period from July 1, 1993 to globins of greater than 110 g/L. The additional case mix December 31, 1993, assessing their co-morbidity, history and clinical data adjustment only changed the associated of vascular access procedures, history of blood transfurisks in the groups with hemoglobins of less than 90 g/L sions, and total hospital days during the six-month entry with the others being unchanged [26] .
period. The severity of disease measures were deter-This study supported the hemoglobin range of 100-110 mined to address the concerns that patients with lower g/L but did not demonstrate any benefit associated with Hcts may have a greater degree of co-morbidity that the higher hemoglobin levels above 110 g/L. One concern could confound analysis. Hcts were computed for paabout this study was the analysis of the patients with tients who had at least 3 measurements in the six-month hemoglobins above 110 g/L. The payment policies in the entry period to better characterize the stability of the United States were restrictive for patients with hemoglo-Hct level and whose measurements would be representabins above 120 g/L such that those patients needed meditive of the six-month fixed survival period. All patients cal indications to justify Epoetin treatment to sustain a were followed for one year assessing the risk of death higher hemoglobin level. Therefore, not all patients were in a Cox regression model and the risk of multiple hospiable to achieve this level of hemoglobin correction in talizations using an Anderson-Gill multiple event model. addition to the fact that the higher hemoglobin group Sensitivity analyses were performed for both studies to may have had more disease. To the extent that the adjustdetermine how many patients would be required in each ment could address these differences, there was no bene-Hct group in order to achieve a significant result in the fit from a mortality standpoint between the group with higher Hct groups [8, 9] . a hemoglobin level of 100-110 g/L and those greater
The risk of first and multiple hospitalizations followed than 110 g/L. This study did clearly establish that patients the mortality pattern previously reported by Madore et with lower hemoglobins were associated with significant al and Locatelli et al but differed in that patients with adverse outcomes.
Hcts of 33-36% had a 8% significantly lower risk than Supporting evidence for the above observational study patients with Hcts of 30-33%. The sensitivity analysis was subsequently reported by Locatelli et al in 1998 in showed that the higher Hct level results associated with a report from the Lombardy dialysis registry in northern hospitalizations required at least 3500 to 4000 patients Italy. In this study, 5,302 prevalent dialysis patients alive in the Hct group of 33-36% in order to determine the on December 31, 1995 were characterized into Hct significance of risk. The mortality associations by Ma et al were similar to the Madore et al and Locatelli et al groups of Ͻ27%, 27-32%, and Ͼ32%. Explanatory vari-morality studies but showed a 4% lower risk of death may be secondary to selection bias in that patients with less co-morbidity and severity of disease may be more at an Hct of 33-36% compared with the Hct group of 30-33%. The sensitivity analysis showed that the mortal-responsive to Epoetin and therefore will require lower doses. The study attempted to adjust for these differ-ity findings in the higher Hct group required at least 16,000 patients in that cell in order to achieve signifi-ences; however, these findings should be viewed only as associations and not causal. A more definitive study cance. The low sensitivity of the mortality event is consistent with all the previous trials including the Besarab et would require a prospective randomized design to demonstrate the direct relationship. al study which was a randomized trail of 600ϩ patients in each cell (Hct 30% vs. 42%) which would have been
The latest study on incident patients demonstrating an association between a lower risk of hospitalization in underpowered to show any impact of the higher Hct level in either the mortality event or the hospitalization patients with Hcts of 36-39% and no adverse mortality risk compared with patients with Hcts of 33-36% sug-event. Therefore, conclusions about the impact of higher Hcts are vulnerable to the size of the reported study.
gests that the concerns raised by the normal Hct trial In November 2001 Collins et al published a study of may be important to reconsider. The clinical reality is incident Medicare hemodialysis patients from 1996 that the dialysis population appears to initiate ESRD through June 30, 1998. Each patient survived to month treatment with an Hct on average of Ͻ30% and increase 9 after the ESRD first service date, and their Hct levels their Hct over a three or four month period toward an were determined in the month 4 to month 9 period of Hct at the midpoint of the DOQI range [29] . Few data survival. The patients were characterized for co-morbidare available in this early correction phase that mimics ity, severity of disease, and Hct levels in a manner that the ramp-up phase of the normal Hct trial which showed was previously used in the Ma et al and Xia et al studies.
an increased risk of death in patients with severe cardiac Followup of the patients was for one year with the outdisease. More investigation is needed to determine if the come being the risk of death or first hospitalization. A higher Hct levels pose an early risk of death to patients. Cox regression model was used with adjustments for age,
The observational data and the study by Marone et al gender, race, diabetes, co-morbidity, severity of disease, would suggest that Hcts of 36-39% may be effective in and Hct level. The analysis also evaluated the relative the hemodialysis population compared with the 33-36% cost of Medicare allowable expenditures based on the Hct current target. From this standpoint, it may be clinically levels. The findings in this incident population were more reasonable to broaden the target range to 33-39%, which definitive than the 1993 prevalent cohort in that the assowould be a more reasonable biologic range based on the ciated risk of death was lowest in the Hct group of 33variability in a patient's Hct level month to month. It is 36% and was not different in the Hct group of 36-39% still prudent to limit the increase in Hcts in Epoetinor the 39ϩ% groups. Based on the previous sensitivity treated patients with cardiac disease to below 42% until studies from these authors, the mortality analysis was more definitive studies are performed. underpowered to demonstrate any impact on mortality. These findings on mortality are consistent with all the ACKNOWLEDGMENT other mortality studies in that there appears to be no in the follow-up period was lowest in the Hct group of E-mail: acollins@nephrology.org 36-39%. The Hct group 39ϩ% showed no difference compared with the Hct group of 33-36%, but this group REFERENCES only had 555 patients which were insufficient to draw 
